循环脂联素修饰CKD患者FGF23对维生素D受体激活的反应
该研究为双盲随机临床试验的事后分析,在CKD患者中比较帕立骨化醇与安慰剂对血清FGF23的影响,并探讨脂联素的修饰作用。结果显示帕立骨化醇显著升高FGF23(P<0.001),且第4四分位脂联素患者的升高幅度更大(P=0.009),安慰剂组无此效应(P=0.49)。基线脂联素和脂联素波动均显著修饰FGF23反应(交互P=0.009和P=0.003)。
要点
- 帕立骨化醇激活VDR显著升高CKD患者血清FGF23水平。
- 高脂联素水平患者FGF23对VDR激活的反应更明显。
- 脂联素与FGF23相关独立于eGFR等混杂因素。
核心结论
- 脂联素是CKD患者FGF23对VDR激活反应的重要修饰因子。
- 小鼠中发现的脂联素-FGF23联系在CKD患者中具有机制相关性。
研究设计与样本
- 双盲随机临床试验的事后分析,纳入CKD患者(NCT01680198)。
- 分析基线脂联素水平及脂联素波动与帕立骨化醇和安慰剂对FGF23反应的交互作用。
主要发现
- 与安慰剂相比,帕立骨化醇显著升高血清FGF23(P<0.001)。
- 第4四分位脂联素患者FGF23升高幅度大于其他四分位(P=0.009),安慰剂组无此效应(P=0.49)。
- 基线脂联素(交互P=0.009)和脂联素波动(交互P=0.003)均显著修饰FGF23对治疗的差异反应。
- 全局相关分析中脂联素与FGF23相关独立于eGFR和其他潜在混杂因素(β=0.22,P=0.003)。
临床怎么用
- CKD患者使用VDR激活剂时,脂联素水平可能有助于预测FGF23升高幅度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The fibroblast growth factor 23 (FGF23) response to phosphate load is suppressed in adiponectin gene null mice and substantially amplified in mice overexpressing the same gene and vitamin D receptor (VDR) activation markedly enhances FGF23 gene expression. METHODS: We performed an analysis of the static (baseline adiponectin levels) and dynamic (fluctuations in adiponectin levels) interactions of serum adiponectin with the FGF23 response to paricalcitol and placebo in the setting of a double-blind, randomized clinical trial in chronic kidney disease (CKD) patients (NCT01680198). RESULTS: As compared with placebo, VDR activation by paricalcitol markedly increased serum FGF23 levels (P < 0.001), and such an increase was amplified in patients in the 4th adiponectin quartile as compared with other quartiles (P = 0.009) while no such an effect was noted in the placebo group (P = 0.49). Both baseline adiponectin (P for interaction = 0.009) and fluctuations in adiponectin levels following paricalcitol and placebo (P for interaction = 0.003) strongly modified the difference in the FGF23 response to these treatments. These interactions were specific because no similar effect modification by other factors with the FGF23 response to VDR activation was found. Furthermore, in a global correlation analysis, adiponectin and FGF23 were interrelated independent of the estimated glomerular filtration rate and other potential confounders (β = 0.22, P = 0.003). CONCLUSIONS: Adiponectin is a strong modifier of the FGF23 response to VDR activation in CKD patients. The adiponectin-FGF23 link discovered in genetically engineered mice is of mechanistic relevance in the FGF23 response to VDR activation in CKD patients.
引用
- Spoto B, Pizzini P, Tripepi G, et al. Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Nephrol Dial Transplant. 2018. PMID: 29304245. doi:10.1093/ndt/gfx344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。